Abstract
Treatment of animals with big endothelin-1 (bET) causes pulmonary hypertension and bronchoconstriction, both in vivo and in perfused lungs. The biological activity of bET requires proteolytic cleavage to ET-1 by endothelin converting enzymes (ECE) and possibly other proteases such as neutral endopeptidase 24.11 (NEP 24.11). Since the role of NEP24.11 in the physiological activation of bET is unclear, we investigated the effects of the selective NEP24.11 inhibitor thiorphan on bET-induced vaso- and bronchoconstriction in the isolated perfused rat lung. We also studied the effects of phosphoramidon and (S)-2-biphenyl-4-yl-1-(1H-tetraol-5-yl)-ehtylaminomethylphosphonic acid (CGS-26303), i.e. agents which block not only NEP24.11 but also ECE. The bET-induced vasoconstriction was much less prominent than the bronchoconstriction, i.e. after exposure for 110 min vascular and airway conductance were decreased by 33% and 80% respectively. The small bET-induced vasoconstriction was attenuated to a similar degree by pretreatment with any of the three protease inhibitors. However, thiorphan up to a concentration of 10µM had only little effect on the bET-induced bronchoconstriction, while 10 µM phosphoramidon or CGS-26303 provided half-maximal and 100µM phosphoramidon complete protection in this model. This profile of inhibitor action suggests that in rat lung ECE is the major enzyme responsible for activation of bET.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 15 October 1996 / Accepted: 29 January 1997
Rights and permissions
About this article
Cite this article
Held, HD., Raschak, M. & Uhlig, S. Rat big endothelin-1-induced bronchoconstriction and vasoconstriction in the isolated perfused rat lung: role of endothelin converting enzyme and neutral endopeptidase 24.11. Naunyn-Schmiedeberg's Arch Pharmacol 355, 619–624 (1997). https://doi.org/10.1007/PL00004992
Issue Date:
DOI: https://doi.org/10.1007/PL00004992